Loading...
Market
Leading Venture Capital Firm in Xaira's Next Funding Round
5
Resolution / Starting Odds
Arch • 13%
Foresite • 13%
F-Prime • 13%
NEA • 13%
Sequoia • 13%
Lux • 13%
Lightspeed • 13%
Two Sigma • 13%
SEC filings, company press releases, or major financial news outlets.
Story
Xaira, Led by CEO Marc Tessier-Lavigne, Raises $1B for RFdiffusion Tech
Apr 25, 2024, 12:25 AM
Xaira, a new biotechnology company, has successfully raised over $1 billion in committed capital, marking one of the largest funding rounds in biotech history. The company, led by CEO Marc Tessier-Lavigne, is set to focus on next-generation technology in biopharma, leveraging AI and RFdiffusion from David Baker's lab. The funding round saw participation from major venture capital firms including Arch, Foresite, F-Prime, NEA, Sequoia, Lux, Lightspeed, and Two Sigma. This significant financial backing underscores the growing interest and investment in tech-driven biopharma solutions.
View original story
Similar markets
Andreessen Horowitz • 20%
Sequoia Capital • 20%
Valor Equity Partners • 20%
Tribe Capital • 20%
Saudi Arabian investors • 20%
Valor Equity Partners • 25%
Vy Capital • 25%
Andreessen Horowitz • 25%
Sequoia Capital • 25%
BITKRAFT Ventures • 10%
HASHED • 10%
Coinbase Ventures • 10%
Spartan Capital • 10%
Foresight Ventures • 10%
Other • 40%
Andreessen Horowitz • 20%
Sequoia Capital • 20%
Tribe Capital • 20%
Valor Equity Partners • 20%
Fidelity • 20%
Venture Capital Firms • 33%
Private Equity Firms • 33%
Crowdfunding • 34%
SoftBank • 25%
Andreessen Horowitz • 25%
Bessemer Venture Partners • 25%
Tiger Global Management • 25%
Cypher Capital • 20%
Polygon Ventures • 20%
Mechanism Capital • 20%
BigBrain VC • 20%
Shima Capital • 20%
